FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model

Johji Fukada, Stefano Schena, Ivan Tack, Phillip Ruiz, Yoshihiko Kurimoto, Manhui Pang, Abdelouahab Aitouche, Tomio Abe, Liliane J. Striker, Si M. Pham

Research output: Contribution to journalArticle

Abstract

Although systemic administration of NO donors has been shown to attenuate the development of neointimal hyperplasia in the balloon injury model, this strategy has not been tested in a model of allograft vasculopathy. In this study, we investigated the effect of FK409, a spontaneous NO releaser, on the development of allograft vasculopathy, using a rat aortic transplant model. Thoracic aortas from ACI rats were transplanted heterotopically into the abdominal aorta of Wistar-Furth rats. Postoperatively, recipients received FK409 orally every 8 hours from the day of transplantation to the time of euthanization. Morphometric and immunohistochemical analyses were performed on the aortic grafts 8 weeks after transplantation. Control allografts showed severe neointimal hyperplasia, which consists mainly of α-actin-containing vascular smooth muscle cells. The FK409-treated allografts showed a dose-dependent reduction (statistically significant compared with the control) in the neointimal thickness as the dose increased from 1 to 10 mg/kg (thrice per day). However, there was no significant difference in the neointimal thickness between groups treated with 10 and with 20 mg/kg. FK409 treatment (10 mg/kg) caused a significant decrease in DNA synthesis (5-bromo-2-deoxyuridine [BrdU] uptake), an increase in DNA fragmentation (terminal deoxynucleotidyltransferase-mediated uridine nick-end labeling [TUNEL]), and upregulation of Fas expression, in the neointimal vascular smooth muscle cells. These data suggest that FK409 attenuates the allograft vasculopathy in a rat aortic transplant model.

Original languageEnglish (US)
Pages (from-to)66-72
Number of pages7
JournalCirculation Research
Volume87
Issue number1
DOIs
StatePublished - Jul 7 2000
Externally publishedYes

Fingerprint

Allografts
Nitric Oxide
Transplants
Vascular Smooth Muscle
Smooth Muscle Myocytes
Hyperplasia
Inbred ACI Rats
Transplantation
Inbred WF Rats
DNA Nucleotidylexotransferase
Uridine
Abdominal Aorta
In Situ Nick-End Labeling
DNA Fragmentation
Bromodeoxyuridine
Thoracic Aorta
Actins
Up-Regulation
DNA
Wounds and Injuries

Keywords

  • Allograft
  • Apoptosis
  • Fas
  • FK409
  • In situ nick-end labeling

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model. / Fukada, Johji; Schena, Stefano; Tack, Ivan; Ruiz, Phillip; Kurimoto, Yoshihiko; Pang, Manhui; Aitouche, Abdelouahab; Abe, Tomio; Striker, Liliane J.; Pham, Si M.

In: Circulation Research, Vol. 87, No. 1, 07.07.2000, p. 66-72.

Research output: Contribution to journalArticle

Fukada, J, Schena, S, Tack, I, Ruiz, P, Kurimoto, Y, Pang, M, Aitouche, A, Abe, T, Striker, LJ & Pham, SM 2000, 'FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model', Circulation Research, vol. 87, no. 1, pp. 66-72. https://doi.org/10.1161/01.RES.87.1.66
Fukada, Johji ; Schena, Stefano ; Tack, Ivan ; Ruiz, Phillip ; Kurimoto, Yoshihiko ; Pang, Manhui ; Aitouche, Abdelouahab ; Abe, Tomio ; Striker, Liliane J. ; Pham, Si M. / FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model. In: Circulation Research. 2000 ; Vol. 87, No. 1. pp. 66-72.
@article{97e05b49f7834721a9ebe242fff2defd,
title = "FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model",
abstract = "Although systemic administration of NO donors has been shown to attenuate the development of neointimal hyperplasia in the balloon injury model, this strategy has not been tested in a model of allograft vasculopathy. In this study, we investigated the effect of FK409, a spontaneous NO releaser, on the development of allograft vasculopathy, using a rat aortic transplant model. Thoracic aortas from ACI rats were transplanted heterotopically into the abdominal aorta of Wistar-Furth rats. Postoperatively, recipients received FK409 orally every 8 hours from the day of transplantation to the time of euthanization. Morphometric and immunohistochemical analyses were performed on the aortic grafts 8 weeks after transplantation. Control allografts showed severe neointimal hyperplasia, which consists mainly of α-actin-containing vascular smooth muscle cells. The FK409-treated allografts showed a dose-dependent reduction (statistically significant compared with the control) in the neointimal thickness as the dose increased from 1 to 10 mg/kg (thrice per day). However, there was no significant difference in the neointimal thickness between groups treated with 10 and with 20 mg/kg. FK409 treatment (10 mg/kg) caused a significant decrease in DNA synthesis (5-bromo-2-deoxyuridine [BrdU] uptake), an increase in DNA fragmentation (terminal deoxynucleotidyltransferase-mediated uridine nick-end labeling [TUNEL]), and upregulation of Fas expression, in the neointimal vascular smooth muscle cells. These data suggest that FK409 attenuates the allograft vasculopathy in a rat aortic transplant model.",
keywords = "Allograft, Apoptosis, Fas, FK409, In situ nick-end labeling",
author = "Johji Fukada and Stefano Schena and Ivan Tack and Phillip Ruiz and Yoshihiko Kurimoto and Manhui Pang and Abdelouahab Aitouche and Tomio Abe and Striker, {Liliane J.} and Pham, {Si M.}",
year = "2000",
month = "7",
day = "7",
doi = "10.1161/01.RES.87.1.66",
language = "English (US)",
volume = "87",
pages = "66--72",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - FK409, a spontaneous nitric oxide releaser, attenuates allograft vasculopathy in a rat aortic transplant model

AU - Fukada, Johji

AU - Schena, Stefano

AU - Tack, Ivan

AU - Ruiz, Phillip

AU - Kurimoto, Yoshihiko

AU - Pang, Manhui

AU - Aitouche, Abdelouahab

AU - Abe, Tomio

AU - Striker, Liliane J.

AU - Pham, Si M.

PY - 2000/7/7

Y1 - 2000/7/7

N2 - Although systemic administration of NO donors has been shown to attenuate the development of neointimal hyperplasia in the balloon injury model, this strategy has not been tested in a model of allograft vasculopathy. In this study, we investigated the effect of FK409, a spontaneous NO releaser, on the development of allograft vasculopathy, using a rat aortic transplant model. Thoracic aortas from ACI rats were transplanted heterotopically into the abdominal aorta of Wistar-Furth rats. Postoperatively, recipients received FK409 orally every 8 hours from the day of transplantation to the time of euthanization. Morphometric and immunohistochemical analyses were performed on the aortic grafts 8 weeks after transplantation. Control allografts showed severe neointimal hyperplasia, which consists mainly of α-actin-containing vascular smooth muscle cells. The FK409-treated allografts showed a dose-dependent reduction (statistically significant compared with the control) in the neointimal thickness as the dose increased from 1 to 10 mg/kg (thrice per day). However, there was no significant difference in the neointimal thickness between groups treated with 10 and with 20 mg/kg. FK409 treatment (10 mg/kg) caused a significant decrease in DNA synthesis (5-bromo-2-deoxyuridine [BrdU] uptake), an increase in DNA fragmentation (terminal deoxynucleotidyltransferase-mediated uridine nick-end labeling [TUNEL]), and upregulation of Fas expression, in the neointimal vascular smooth muscle cells. These data suggest that FK409 attenuates the allograft vasculopathy in a rat aortic transplant model.

AB - Although systemic administration of NO donors has been shown to attenuate the development of neointimal hyperplasia in the balloon injury model, this strategy has not been tested in a model of allograft vasculopathy. In this study, we investigated the effect of FK409, a spontaneous NO releaser, on the development of allograft vasculopathy, using a rat aortic transplant model. Thoracic aortas from ACI rats were transplanted heterotopically into the abdominal aorta of Wistar-Furth rats. Postoperatively, recipients received FK409 orally every 8 hours from the day of transplantation to the time of euthanization. Morphometric and immunohistochemical analyses were performed on the aortic grafts 8 weeks after transplantation. Control allografts showed severe neointimal hyperplasia, which consists mainly of α-actin-containing vascular smooth muscle cells. The FK409-treated allografts showed a dose-dependent reduction (statistically significant compared with the control) in the neointimal thickness as the dose increased from 1 to 10 mg/kg (thrice per day). However, there was no significant difference in the neointimal thickness between groups treated with 10 and with 20 mg/kg. FK409 treatment (10 mg/kg) caused a significant decrease in DNA synthesis (5-bromo-2-deoxyuridine [BrdU] uptake), an increase in DNA fragmentation (terminal deoxynucleotidyltransferase-mediated uridine nick-end labeling [TUNEL]), and upregulation of Fas expression, in the neointimal vascular smooth muscle cells. These data suggest that FK409 attenuates the allograft vasculopathy in a rat aortic transplant model.

KW - Allograft

KW - Apoptosis

KW - Fas

KW - FK409

KW - In situ nick-end labeling

UR - http://www.scopus.com/inward/record.url?scp=0034617060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034617060&partnerID=8YFLogxK

U2 - 10.1161/01.RES.87.1.66

DO - 10.1161/01.RES.87.1.66

M3 - Article

C2 - 10884374

AN - SCOPUS:0034617060

VL - 87

SP - 66

EP - 72

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 1

ER -